USPTO Watch

Rulemaking, discipline, designations, and decisions inside the Office.

USPTO Watch · PTAB Appeal

Federal Circuit Affirms PTAB Obviousness Rulings Against Netlist on Two Memory Module Patents

In a precedential November 13 opinion, the court affirmed the Board's determinations that all claims of Netlist's '417 and '215 patents are unpatentable as obvious, and held that "the relevant question is whether the combination is operable for the purposes of the claimed invention."

USPTO Watch · PTAB Appeal

Federal Circuit Affirms PTAB Rulings for DDC Technology on Three Virtual Reality Viewer Patents in Google Appeal

In a precedential November 5 opinion, the court affirmed the Board's determinations in IPR2023-00707, IPR2023-00709, and IPR2023-00711 that Google did not prove the surviving claims obvious, and repeated that it has rejected any formal burden-shifting framework in evaluating the four Graham factors and that objective indicia of nonobviousness must be considered in every case.

USPTO Watch · PTAB Appeal

Federal Circuit Vacates PTAB Ruling for Maschio Gaspardo on Seed Drill Patent in Precision Planting Appeal

In a nonprecedential October 30 opinion, the court held that no substantial evidence supports the Board's finding that the Fiorido reference does not disclose a thrust-bearing element, and sent the obviousness question on claims 1-3, 7-12, and 16 of U.S. Patent No. 8,770,121 back to the Board.

USPTO Watch · PTAB Appeal

Federal Circuit Affirms PTAB Rulings for BeSang on Stackable Memory Patent in Micron and Intel Appeals

In a nonprecedential October 30 opinion, the court affirmed two Board decisions holding that Micron did not show claims 13-17, and Intel did not show claims 1 and 13-17, of U.S. Patent No. 7,378,702 unpatentable.

USPTO Watch · PTAB Appeal

Federal Circuit Affirms Obviousness Ruling on Network Intrusion Monitoring Patent in BT Americas Appeal

In a nonprecedential October 29 opinion, the court upheld the Board's ruling that claims 1 to 25 of U.S. Patent No. 7,895,641 are unpatentable as obvious, and again rejected the argument that the Board lacks jurisdiction over an expired patent.

USPTO Watch · PTAB Appeal

Federal Circuit Grants USPTO Director's Remand Request in Percept IPR Appeal Over Percept's Opposition

In a nonprecedential October 28 order, the court sent IPR2023-00495 back to the agency for the limited purpose of letting the Director further explain the issues raised in the order and the motion, which concern the reasoning on how the prior art meets a disputed eye tracking limitation.

USPTO Watch · PTAB Appeal

Federal Circuit Holds Word Metadata Can Corroborate an Inventor's Conception Testimony

In a precedential October 19 opinion, the court affirmed a Board decision that Google had not shown claims 1-23 of U.S. Patent No. 6,728,704 unpatentable, after the Board found that the inventors had conceived of the invention before an earlier-filed reference and had been diligent until they filed.

USPTO Watch · PTAB Appeal

Federal Circuit Affirms PGR Loss for UPL Fungicide Patent and Board's Denial of Leave to Seek Sanctions

In a nonprecedential October 14 opinion, the court affirmed the Board's holding that all challenged claims of U.S. Patent No. 11,445,727 are unpatentable, and found no abuse of discretion in the Board's reliance on the safe harbor in 37 C.F.R. 42.11(d)(2) to deny Syngenta leave to file a sanctions motion, because UPL had already withdrawn its reliance on the field-trial data Syngenta challenged.

USPTO Watch · Patent Term Extension

FDA Sets MONOFERRIC's Regulatory Review Period for Patent Term Extension

In an October 9 Federal Register notice, FDA determined that MONOFERRIC's regulatory review period is 3,292 days. The notice states that the USPTO received a patent term restoration application from Pharmacosmos Holding A/S for MONOFERRIC (U.S. Patent Nos. 8,815,301 and 10,414,831) and that the applicant seeks 1,136 days of patent term extension.

USPTO Watch · Explainer

What It Means When the PTAB Calls a Decision "Informative"

In August 2026 the USPTO designated a Markush-claim appeal decision as informative after a stakeholder nominated it. Informative decisions are not binding, but under the Board's procedures they set out norms that should be followed in most cases, absent justification.